Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bijaya Sharma

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Cell Reports. Medicine|October 15, 2025
Pan-cancer spatial characterization of key immune biomarkers in the tumor microenvironmentJames R Lindsay, Jennifer Altreuter, Joao V Alessi, et al.
Cell Reports. Medicine|September 20, 2023
Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer statesJackson Nyman, Thomas Denize, Ziad Bakouny, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer statesJackson Nyman, Thomas Denize, Ziad Bakouny, et al.
Journal for Immunotherapy of Cancer|November 26, 2021
Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancerJoao V Alessi, Biagio Ricciuti, Stephanie L Alden, et al.
Science Advances|November 22, 2023
ATM deficiency confers specific therapeutic vulnerabilities in bladder cancerYuzhen Zhou, Judit Börcsök, Elio Adib, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2023
Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non-Small Cell Lung CancerBiagio Ricciuti, Arielle Elkrief, Joao Alessi, et al.
Clinical Lung Cancer|February 28, 2025
Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (≥50%) PatientsAdriana P C Barrichello, Arielle Elkrief, Biagio Ricciuti, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 29, 2023
Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLCJoao V Alessi, Xinan Wang, Arielle Elkrief, et al.
JAMA Oncology|June 16, 2022
Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression LevelsBiagio Ricciuti, Xinan Wang, Joao V Alessi, et al.
JCO Precision Oncology|September 4, 2025
Immunoprofiling at an Institutional Scale Reveals That High Numbers of Intratumoral CD8<sup>+</sup> and PD-1<sup>+</sup> Cells Predict Superior Patient Survival Across Major Cancer Types Independent of Major Risk FactorsJoao V Alessi, James R Lindsay, Anita Giobbie-Hurder, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Cell Reports. Medicine|October 15, 2025
Pan-cancer spatial characterization of key immune biomarkers in the tumor microenvironmentJames R Lindsay, Jennifer Altreuter, Joao V Alessi, et al.
Cell Reports. Medicine|September 20, 2023
Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer statesJackson Nyman, Thomas Denize, Ziad Bakouny, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer statesJackson Nyman, Thomas Denize, Ziad Bakouny, et al.
Journal for Immunotherapy of Cancer|November 26, 2021
Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancerJoao V Alessi, Biagio Ricciuti, Stephanie L Alden, et al.
Science Advances|November 22, 2023
ATM deficiency confers specific therapeutic vulnerabilities in bladder cancerYuzhen Zhou, Judit Börcsök, Elio Adib, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2023
Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non-Small Cell Lung CancerBiagio Ricciuti, Arielle Elkrief, Joao Alessi, et al.
Clinical Lung Cancer|February 28, 2025
Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (≥50%) PatientsAdriana P C Barrichello, Arielle Elkrief, Biagio Ricciuti, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 29, 2023
Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLCJoao V Alessi, Xinan Wang, Arielle Elkrief, et al.
JAMA Oncology|June 16, 2022
Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression LevelsBiagio Ricciuti, Xinan Wang, Joao V Alessi, et al.
JCO Precision Oncology|September 4, 2025
Immunoprofiling at an Institutional Scale Reveals That High Numbers of Intratumoral CD8<sup>+</sup> and PD-1<sup>+</sup> Cells Predict Superior Patient Survival Across Major Cancer Types Independent of Major Risk FactorsJoao V Alessi, James R Lindsay, Anita Giobbie-Hurder, et al.
Pageof 2